Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study

Endoscopy ◽  
2021 ◽  
Author(s):  
Annieke W. Gotink ◽  
Steffi Elisabeth Maria van de Ven ◽  
Fiebo JW ten Kate ◽  
Daan Nieboer ◽  
Lucia Suzuki ◽  
...  

<b>Background and study aims:</b> There is a risk for lymph node metastases (LNM) after endoscopic resection of early esophageal adenocarcinoma (EAC). The aim of this study was to develop and internally validate a prediction model that estimates the individual metastases risk in patients with pT1b EAC. <b>Patients and methods:</b> This is a nationwide, retrospective, multicenter cohort study. Patients with pT1b EAC and treated with endoscopic resection and/or surgery between 1989 and 2016 were included. Primary endpoint was the presence of LNM in surgical resection specimen or the detection of metastases during follow-up. All resection specimens were histologically reassessed by specialized gastrointestinal pathologists. Subdistribution hazard regression analysis was used to develop a prediction model. The discriminative ability of this model was assessed using the c-statistic. <b>Results:</b> 248 patients with pT1b EAC were included. Metastases were seen in 78 patients, and the 5-year cumulative incidence was 30.9% (95% CI 25.1%-36.8%). The risk for metastases increased with submucosal invasion depth (subdistribution hazard ratio [SHR] 1.08, 95% CI 1.02-1.14, for every increase of 500 μm), for tumors with lymphovascular invasion (SHR 2.95, 95% CI 1.95-4.45) and for larger tumors (SHR 1.23, 95% CI 1.10-1.37, for every increase of 10 mm). The model demonstrated a good discriminative ability (c-statistic 0.81, 95% CI 0.75-0.86). <b>Conclusions:</b> One third of patients with pT1b EAC experienced metastases within 5 years. The probability for developing post resection metastases can be estimated with a personalized predicted risk score incorporating tumor invasion depth, tumor size and lymphovascular invasion. This model needs to be externally validated before implementation into clinical practice.

2014 ◽  
Vol 24 (2) ◽  
pp. 303-311 ◽  
Author(s):  
Afra Zaal ◽  
Ronald P. Zweemer ◽  
Michal Zikán ◽  
Ladislav Dusek ◽  
Denis Querleu ◽  
...  

ObjectiveIn this study, we aimed to describe the value of pelvic lymph node dissection (LND) after sentinel lymph node (SN) biopsy in early-stage cervical cancer.MethodsWe performed a retrospective multicenter cohort study in 8 gynecological oncology departments. In total, 645 women with International Federation of Gynecology and Obstetrics stage IA to IIB cervical cancer of squamous, adeno, or adenosquamous histologic type who underwent SN biopsy followed by pelvic LND were enrolled in this study. Radioisotope tracers and blue dye were used to localize the sentinel node, and pathologic ultrastaging was performed.ResultsAmong the patients with low-volume disease (micrometastases and isolated tumor cells) in the sentinel node, the overall survival was significantly better (P = 0.046) if more than 16 non-SNs were removed. No such significant difference in survival was detected in patients with negative or macrometastatic sentinel nodes.ConclusionsOur findings indicate that in patients with negative or macrometastatic disease in the sentinel nodes, an additional LND did not alter survival. Conversely, our data suggest that the survival of patients with low-volume disease is improved when more than 16 additional lymph nodes are removed. If in a prospective trial our data are confirmed, we would suggest a 2-stage operation.


2010 ◽  
Vol 18 (6) ◽  
pp. 1657-1664 ◽  
Author(s):  
Paul D. Gobardhan ◽  
Sjoerd G. Elias ◽  
Eva V. E. Madsen ◽  
Bob van Wely ◽  
Frits van den Wildenberg ◽  
...  

Surgery ◽  
2011 ◽  
Vol 150 (6) ◽  
pp. 1048-1057 ◽  
Author(s):  
Aleksandra Popadich ◽  
Olga Levin ◽  
James C. Lee ◽  
Stephanie Smooke-Praw ◽  
Kevin Ro ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document